Search

BioMarin Pharmaceutical Inc

Lezárt

SzektorEgészségügy

66.34 0.21

Áttekintés

Árfolyamváltozás megosztása

24 óra

Jelenlegi

Minimum

65.31

Maximum

66.63

Fő mutatók

By Trading Economics

Bevétel

-61M

45M

Értékesítés

224M

990M

P/E

Szektor átlag

176.297

56.659

Egy részvényre jutó nyereség

0.9

Profit margin

4.523

Munkavállalók

3,221

EBITDA

50M

222M

Ajánlások

By TipRanks

Ajánlások

Erős vétel

12 hónapos előrejelzés

+39.86% upside

Osztalékok

By Acuity

Következő eredményjelentés

2026. okt. 26.

Piaci statisztika

By TradingEconomics

Piaci kapitalizáció

1B

13B

Előző nyitás

66.13

Előző zárás

66.34

Hangulat hírek alapján

By Acuity

28%

72%

74 / 339 Rangsor szerint Healthcare

BioMarin Pharmaceutical Inc Chart

A múltbeli teljesítmény nem megbízható mutatója a jövőbeli eredményeknek.

Kapcsolódó hírek

2026. szept. 4. 20:07 UTC

BioMarin Pharmaceutical Inc shares are higher in Friday's session, despite earlier pullbacks. No specific news was identified to explain the movement.

2026. szept. 3. 19:46 UTC

News
Social Media

BioMarin Pharmaceutical completes a $275 million acquisition, impacting its strategic positioning. Shares are lower during Thursday's session amid broader biotech M&A activity.

2026. szept. 2. 23:01 UTC

BioMarin Pharmaceutical Inc. shares declined in after-market trading, reversing earlier gains amid broader market concerns tied to U.S.-Iran tensions and rising oil prices.

2026. szept. 1. 19:46 UTC

News

BioMarin Pharmaceutical completed its acquisition of Alesta Therapeutics today. Despite this, shares are lower amid integration concerns and ongoing clinical evaluations.

2026. aug. 31. 21:01 UTC

BioMarin Pharmaceutical shares are lower in after-market trading amid cautious market sentiment influenced by hawkish comments from Fed Chair Kevin Warsh on inflation.

2026. aug. 24. 19:26 UTC

Social Media

BioMarin Pharmaceutical announced its $275 million acquisition of Alesta Therapeutics. Shares are trading lower amid ongoing market volatility and geopolitical tensions.

2026. aug. 21. 19:16 UTC

Biomarin Pharmaceutical Inc shares are lower today, despite earlier gains. Broader market volatility linked to rising crude oil prices may be influencing sentiment.

2026. aug. 20. 19:16 UTC

News
Social Media

BioMarin Pharmaceutical shares are lower despite BMO initiating coverage with an Outperform rating and a price target of $98.

2026. aug. 19. 23:51 UTC

News

Biomarin Pharmaceutical Inc shares are lower in after-market hours amid a broader Biotechnology sector decline, despite a recent $275 million acquisition of Alesta Therapeutics.

2026. aug. 18. 23:41 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, reflecting broader market declines amid profit-taking in technology and concerns over rising bond yields.

2026. aug. 17. 19:16 UTC

News

BioMarin shares are lower despite price target increases from Barclays and Piper Sandler, reflecting ongoing downward performance trends in recent sessions.

2026. aug. 14. 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today, diverging from recent gains. Broader market sentiment is mixed amid a decline in U.S. retail sales.

2026. aug. 13. 22:36 UTC

Biomarin Pharmaceutical shares are higher in after-market hours, reflecting broader market positivity following the S&P 500's record close and easing inflation concerns.

2026. aug. 12. 23:01 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading, with no specific news identified to explain the decline following five consecutive sessions of gains.

2026. aug. 11. 19:56 UTC

Biomarin Pharmaceutical Inc shares are higher, continuing a recent upward trend. Market focus is on upcoming economic indicators, including the Consumer Price Index report.

2026. aug. 10. 23:26 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market trading. Broader market sentiment remains cautious amid geopolitical tensions affecting investor confidence.

2026. aug. 7. 23:16 UTC

Biomarin Pharmaceutical Inc shares are lower in after-market hours. The broader market declined following recent labor market data affecting Federal Reserve rate hike expectations.

2026. aug. 6. 23:02 UTC

News

BioMarin Pharmaceutical reported second-quarter EPS of $1.20, surpassing estimates. Shares are trading higher in after-market hours following strong revenue growth and raised guidance.

2026. aug. 5. 23:56 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market hours amid routine trading, with no specific news identified to explain the movement.

2026. aug. 4. 19:46 UTC

Biomarin Pharmaceutical Inc shares are higher, supported by broader market strength amid a decline in crude oil prices, easing inflation concerns.

2026. aug. 3. 23:31 UTC

News

Biomarin Pharmaceutical shares are lower in after-market hours amid concerns over stagnant operating margins and below-average returns on capital, raising investor caution.

2026. júl. 31. 20:06 UTC

Biomarin Pharmaceutical Inc shares are lower today amid broader market declines, pressured by rising Treasury yields and increased crude oil prices.

2026. júl. 30. 19:08 UTC

Biomarin Pharmaceutical Inc shares are lower today, reflecting a decline since Wednesday's close amid broader economic uncertainty from rising jobless claims and weak GDP growth.

2026. júl. 29. 18:14 UTC

Biomarin Pharmaceutical Inc shares are lower today, with no specific news identified. Market sentiment remains mixed amid speculation on potential Federal Reserve rate hikes.

2026. júl. 28. 18:02 UTC

Biomarin Pharmaceutical is trading higher, benefiting from a strong Biotechnology sub-sector trend. Shares reached a peak earlier in the session amid favorable market conditions.

2026. júl. 27. 19:01 UTC

News

BioMarin Pharmaceutical announced a collaboration with the n-Lorem Foundation to develop a treatment for ReNU syndrome, boosting shares during Monday's session.

2026. júl. 24. 15:46 UTC

Biomarin Pharmaceutical shares are higher today, reflecting a broader market rebound amid a significant decline in oil prices.

2026. júl. 22. 23:31 UTC

Biomarin Pharmaceutical shares traded roughly flat in after-market hours amid rising crude oil prices and geopolitical tensions affecting market sentiment.

2026. júl. 21. 15:36 UTC

Biomarin Pharmaceutical Inc shares are higher as the Nasdaq gains, supported by strong technology stocks. The stock trades above its 20-day moving average.

2026. júl. 20. 23:51 UTC

Biomarin Pharmaceutical Inc shares are higher in after-market trading, remaining above their 20-day moving average amid broader market concerns over interest rates and economic growth.

Társak összehasonlítása

Árváltozás

BioMarin Pharmaceutical Inc Előrejelzés

Célár

By TipRanks

39.86% elmozdulás felfelé

12 hónapos előrejelzés

Átlag 93.05 USD  39.86%

Magas 124 USD

Alacsony 60 USD

20 Wall Street elemző 12 hónapos célárain alapulva a(z)BioMarin Pharmaceutical Inc termékhez az elmúlt 3 hónapban.

Értékelési konszenzus

By TipRanks

Erős vétel

20 ratings

15

Vétel

5

Tartás

0

Eladás

Hangulat

By Acuity

74 / 339 Rangsor szerint Egészségügy

Hangulat hírek alapján

Bullish bizonyíték

Volatilitás

Átlag alatti

Hírmennyiség (RCV)

Átlag feletti

Pénzügyek

Értékesítési és adminisztrációs költségek

Üzemeltetési költségek

Adózás előtti nyereség

Értékesítés

Értékesítési költség

Értékesítési bruttó nyereség

Kamatköltség a hitelre

EBITDA

Üzemi nyereség

$

Rólunk BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat